ImmunoGen, Inc. (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

• Publication date: March 2012

ImmunoGen, Inc. (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary ImmunoGen, Inc. (ImmunoGen) is a biopharmaceutical company engaged in developing anticancer therapeutics. The company develops product candidates that utilize its proparietary Targeted Antibody Payload (TAP) technology. ImmunoGen's most advanced wholly owned product candidate lorvotuzumab mertansine (IMGN901), a TAP compound used as a ...

ImmunoGen, Inc. (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

ImmunoGen, Inc. (ImmunoGen) is a biopharmaceutical company engaged in developing anticancer therapeutics. The company develops product candidates that utilize its proparietary Targeted Antibody Payload (TAP) technology. ImmunoGen's most advanced wholly owned product candidate lorvotuzumab mertansine (IMGN901), a TAP compound used as a potential treatment for small cell lung cancer, Merkel cell carcinoma, ovarian cancer, and multiple myeloma. Its most advanced TAP compound, Trastuzumab emtansine (T-DM1, formerly known as trastuzumab-DM1), is in Phase III clinical trials for two indications and is being developed with the collaboration of Genentech, a member of the Roche Group. Additionally, the company also develops products such as SAR3419, IMGN388, other immunogen compounds include IMGN529 and IMGN853. ImmunoGen is headquartered in Waltham, Massachusetts, the US.

ImmunoGen, Inc. (IMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's mergers and acquisitions (M&As), partnerships and financings. The report provides detailed information on mergers and acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including mergers and acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as mergers and acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Pathology Industry in the United Kingdom

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 9
ImmunoGen, Inc., Pharmaceuticals & Healthcare Deals By Type, 2006 to YTD 2012 10
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012 11
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2006 to YTD 2012 12
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 13
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 14
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 15
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 16
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 17
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2006 to YTD 2012 18
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deal Details 19
Partnerships 19
ImmunoGen Enters Into Partnership With Novartis 19
Sanofi-Aventis Extends Research Collaboration With ImmunoGen 20
Licensing Agreements 21
ImmunoGen Extends Its License Agreement With Sanofi-Aventis 21
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 22
ImmunoGen Enters Into Second Licensing Agreement With Amgen 23
ImmunoGen Enters Into Licensing Agreement With Amgen 24
ImmunoGen Enters Into Licensing Agreement With Genentech For Cancer Technology 25
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare 26
ImmunoGen Enters Into Licensing Agreement With Centocor Ortho Biotech 27
ImmunoGen Enters Into Licensing Agreement With Sanofi-Aventis 29
ImmunoGen Enters Into Licensing Agreement With Biotest 30
ImmunoGen Extends Its Agreement With Millennium Pharmaceuticals 31
Equity Offering 32
ImmunoGen Completes An Underwritten Public Offering Of $84 Million 32
ImmunoGen Completes Public Offering Of $83 Million 34
ImmunoGen Completes Public Offering Of $40 Million 36
ImmunoGen Completes Private Placement Of $25 Million 38
ImmunoGen, Inc. - Key Competitors 40
Key Employees 41
Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Oct 27, 2011: Neoprobe Reports Revenue Of $2.5m In Q1 Fiscal 2012 43
Aug 03, 2011: ImmunoGen Reports Total Revenues Of $6.5m For Q4 Fiscal 2011 44
Apr 28, 2011: ImmunoGen Reports Net Loss Of $15m For Q3 Fiscal 2011 44
Jan 27, 2011: ImmunoGen Reports Net Loss Of $14.2 Million For Q2 Fiscal 2011 45
Oct 28, 2010: ImmunoGen Reports Net Loss Of $12.9 Million For Q1 Fiscal 2011 45
Aug 04, 2010: ImmunoGen Reports Net Loss Of $13.4 Million For Q4 Fiscal 2010 45
Apr 29, 2010: ImmunoGen Reports Net Loss Of $12.1 Million For Q3 Fiscal 2010 46
Jan 28, 2010: ImmunoGen Reports Net Loss Of $13 Million For Q2 Fiscal 2010 47
Oct 29, 2009: ImmunoGen Q1 Fiscal 2010 Net Loss Increases 47
Aug 06, 2009: ImmunoGen Reports Net Loss Of $10.8 million For Q4 Fiscal 2009 47
Apr 30, 2009: ImmunoGen Q3 Fiscal 2009 Net Loss Narrows 48
Jan 29, 2009: ImmunoGen Q2 Fiscal 2009 Net Loss Increases 48
Oct 27, 2008: Immunogen, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 48
Aug 07, 2008: Immunogen, Inc. Reports Fourth Quarter And Fiscal Year 2008 Financial Results 50
May 01, 2008: Immunogen, Inc. Reports Third Quarter Fiscal Year 2008 Financial Results 51
Jan 31, 2008: Immunogen, Inc. Reports Second Quarter Fiscal Year 2008 Financial Results 53
Nov 01, 2007: Immunogen, Inc. Reports First Quarter Fiscal Year 2008 Financial Results 54
Aug 09, 2007: Immunogen, Inc. Reports Fourth Quarter And Fiscal Year 2007 Financial Results 56
May 03, 2007: Immunogen, Inc. Reports Third Quarter Fiscal Year 2007 Financial Results 57
Feb 01, 2007: Immunogen, Inc. Reports Second Quarter Fiscal Year 2007 Financial Results 59
Nov 02, 2006: Immunogen, Inc. Reports First Quarter Fiscal Year 2007 Financial Results 61
Aug 10, 2006: Immunogen, Inc. Reports Fourth Quarter And Fiscal Year 2006 Financial Results; Company Provides Business Update 62
May 04, 2006: Immunogen, Inc. Reports Third Quarter Fiscal Year 2006 Financial Results; Company Provides Business Update 64
Feb 02, 2006: Immunogen, Inc. Reports Second Quarter Fiscal Year 2006 Financial Results; Company Provides Business Update 65
Nov 03, 2005: Immunogen, Inc. Reports First Quarter Fiscal Year 2006 Financial Results 66
Aug 11, 2005: Immunogen, Inc. Reports Fourth Quarter And Fiscal Year 2005 Financial Results; Company Provides Business Update 68
May 05, 2005: Immunogen, Inc. Reports Third Quarter Fiscal Year 2005 Financial Results 69
Feb 03, 2005: Immunogen, Inc. Reports Second Quarter Fiscal Year 2005 Financial Results; Company Provides Business Update 71
Nov 04, 2004: Immunogen, Inc. Reports First Quarter Fiscal Year 2005 Financial Results; Company Provides Business Update 72
Aug 12, 2004: Immunogen, Inc. Reports Fourth Quarter And Fiscal Year 2004 Financial Results; Revenue From Partners Increased Substantially Over 2003 Levels 73
May 13, 2004: Immunogen, Inc. Reports Fiscal Year 2004 Third Quarter Financial Results; Company Provides Business Update 74
Feb 12, 2004: Immunogen, Inc. Reports Fiscal Year 2004 Second Quarter Financial Results; Company Provides Business Update 76
Nov 06, 2003: Immunogen, Inc. Reports First Quarter 2004 Financial Results; Company Provides Business Update 77
Aug 07, 2003: Immunogen, Inc. Reports Fourth Quarter And Fiscal Year 2003 Financial Results 78
May 08, 2003: Immunogen, Inc. Reports Third Quarter 2003 Results; Company Provides Business Update 80
Feb 06, 2003: Immunogen, Inc. Reports Second Quarter 2003 Results; Company Provides Business Update 81
Nov 07, 2002: Immunogen, Inc. Reports First Quarter 2003 Results 83
Aug 08, 2002: Immunogen, Inc. Reports Fiscal Year 2002 Results 84
May 09, 2002: Immunogen, Inc. Reports Third-Quarter Results 86
Feb 07, 2002: Immunogen, Inc. Reports Second-Quarter Results 87
Nov 08, 2001: Immunogen, Inc. Reports First-Quarter Results 88
Aug 16, 2001: Immunogen, Inc. Reports Financial Results For Fiscal Year 2001 89
May 10, 2001: Immunogen, Inc. Reports Third Quarter Results, Beating Expectations By $0.01 90
Feb 08, 2001: Immunogen, Inc. Reports Second Quarter Results 92
Oct 26, 2000: Immunogen, Inc. Reports First Quarter Financial Results 93
Aug 17, 2000: Immunogen, Inc. Reports Year-End Financial Results 93
Apr 20, 2000: Immunogen, Inc. Reports Third Quarter Financial Results 94
Jan 19, 2000: Immunogen, Inc. Reports Second Quarter Results 94
Corporate Communications 95
Jan 18, 2011: ImmunoGen Appoints Theresa Wingrove As Vice President, Regulatory Affairs 95
Jun 22, 2010: ImmunoGen Announces Vice President Promotions In Product Development 95
Dec 17, 2009: ImmunoGen Names New Vice President Of Regulatory Affairs And Quality 95
Dec 17, 2009: ImmunoGen Appoints Suzanne Cadden As Vice President, Regulatory Affairs And Quality 96
Nov 11, 2009: ImmunoGen Announces Executive Changes 96
Aug 17, 2009: ImmunoGen Appoints Peter Williams As Vice President, Business Development 97
Jan 09, 2009: ImmunoGen Appoints Gregory Perry As Chief Financial Officer 97
Government and Public Interest 97
Nov 02, 2010: ImmunoGen Presents On Molecular Targets And Cancer Therapeutics At 22nd EORTC-NCI-AACR Symposium 97
Product News 98
Dec 15, 2006: Immunogen, Inc. Announces Presentation Of First Clinical Data For Genentechs Trastuzumab-Mcc-Dm1 98
Dec 12, 2009: Immunogen, Inc. Announces Positive Trastuzumab-Dm1 Clinical Data Reported At The San Antonio Breast Cancer Symposium 99
Dec 11, 2006: Immunogen, Inc. Announces Presentation At Ash Of Encouraging Findings With Hun901-Dm1 For The Treatment Of Multiple Myeloma 99
Dec 08, 2007: Immunogen, Inc. Announces Encouraging Clinical Findings Reported At Ash Annual Meeting With Targeted Anticancer Compounds Imgn901 (Hun901-Dm1) And Ave1642 101
Dec 07, 2009: Sar3419 Phase I Study Results In Non-Hodgkins Lymphoma At Ash 102
Dec 04, 2002: Immunogen, Inc. Announces Start Of Phase Ii Study With Hun901-Dm1 In Patients With Relapsed Small-Cell Lung Cancer 102
Nov 28, 2001: Boehringer Ingelheim And Immunogen Sign Exclusive License Agreement 103
Nov 22, 2002: Immunogen, Inc. And British Biotech Plc Announce Completion Of Hun901-Dm1 Phase I Study 103
Nov 17, 2010: ImmunoGen Announces Clinical Data Presentations At 52nd ASH Annual Meeting And Exposition 104
Nov 17, 2009: ImmunoGen Reports Clinical Data On IMGN901 In Treatment Of MCC 104
Nov 14, 2011: ImmunoGen Earns Milestone Payment From Amgen With IND Achievement For Second TAP Compound 105
Nov 14, 2005: Immunogen, Inc. Announces Clinical And Preclinical Findings With Tap Compounds To Be Presented At The Aacr-Nci-Eortc International Conference On Molecular Targets And Cancer Therapeutics 105
Nov 10, 2006: Immunogen, Inc. Announces Presentation Of Hun901-Dm1 Clinical Data At Eortc-Nci-Aacr Conference Showing Compound Is Well Tolerated And Demonstrates Anticancer Activity 106
Nov 08, 2000: Immunogen Reports Favorable Preclinical Results For Hun901-Dm1/Bb-10901 107
Nov 03, 2011: ImmunoGen Earns Milestone From Amgen With IND Achievement 107
Nov 01, 2001: Immunogens Partner Genentech Presents Favorable Preclinical Results Of Trastuzumab-Dm1 At Aacr-Nci-Eortc Meeting 108
Oct 27, 2008: Immunogen, Inc. Earns $4 Million Milestone Payment With Sanofi-Aventis Initiation Of A Phase Ii Trial With Ave1642 108
Oct 24, 2007: Immunogen, Inc. Reports New Clinical And Preclinical Data At Aacr-Nci-Eortc 109
Oct 17, 2007: Immunogen, Inc. Earns Milestone With Start Of Sar3419 Clinical Testing 110
Oct 15, 2002: Boehringer Ingelheim And Immunogen Achieve Milestone In Development Of Novel Anti-Cancer Agent 110
Oct 04, 2006: Immunogen Announces Initiation Of Clinical Testing Of Ave1642 Anticancer Compound In Collaboration With Sanofi-Aventis 111
Sep 16, 2009: Amgen Licenses Exclusive Right To Use ImmunoGen’s TAP Technology 111
Sep 07, 2005: Immunogen, Inc. Initiates Clinical Testing Of Hun901-Dm1 For Treatment Of Multiple Myeloma; Study Expands Hun901-Dm1 Clinical Development Program 112
Jul 31, 2009: Immunogen Announces Encouraging New Clinical Data With The Companys Imgn901 Compound In The Treatment Of Small-Cell Lung Cancer 112
Jul 31, 2009: ImmunoGen Provides New Clinical Data On IMGN901 113
Jun 24, 2010: Immunogen, Inc. Earns Milestone With Start Of Sar650984 Clinical Trial 114
Jun 24, 2005: Immunogen, Inc. Announces Initiation Of Clinical Testing Of Its Huc242-Dm4 Anticancer Compound; Companys Second Wholly-Owned Tap Compound Advances Into Clinical Testing 114
Jun 24, 2002: Immunogen, Inc. Provides Update On Relationship With Glaxosmithkline And Also On The Status Of Trastuzumab-Dm1 115
May 30, 2009: Immunogen, Inc. Announces Encouraging Trastuzumab-Dm1 Phase Ii Clinical Findings Presented At Asco 116
May 29, 2001: British Biotech And Immunogen Begin Patient Enrollment For The Phase I/Ii Trial Of Bb-10901/Hun901-Dm1 In Small Cell Lung Cancer 116
May 24, 2010: ImmunoGen Announces Clinical Data Presentations At Upcoming ASCO Annual Meeting 117
May 21, 2002: Immunogen, Inc. Announces Presentation Of Data On Cantuzumab Mertansine At The Annual Meeting Of The American Society Of Clinical Oncology 118
May 20, 2002: Immunogen, Inc. And British Biotech Plc Announce Presentation Of Data From Ongoing Phase I/Ii Clinical Study Of Hun901-Dm1/Bb-10901 At The 2002 Meeting Of The American Society Of Clinical Oncology 119
May 17, 2005: Immunogen, Inc. Reports Initial Phase Ii Findings With Its Hun901-Dm1 Anticancer Compound In The Treatment Of Small-Cell Lung Cancer; Companys Lead Tap Compound Demonstrates Objective Evidence Of Anticancer Activity 119
May 14, 2009: Immunogen, Inc. Announces Trastuzumab-Dm1 Presentations At The 2009 American Society For Clinical Oncology Annual Meeting 120
Apr 17, 2005: Immunogen, Inc. Reports Data At Aacr On The Companys Huc242-Dm4 Anticancer Compound 121
Mar 08, 2010: Immunogen, Inc. Announces Orphan Drug Designation Granted To Imgn901 For Treatment Of Merkel Cell Carcinoma By Us Fda And Eu Comp 121
Mar 02, 2009: Immunogen, Inc. Earns Milestone Payment With Genentechs Start Of Trastuzumab-Dm1 (T-Dm1) Phase Iii Clinical Testing; Other T-Dm1 Progress Reported 122
Feb 16, 2000: Immunogen, Inc. Provides Corporate And Clinical Update At 2nd Annual Bio Ceo & Investor Conference 122
Jan 31, 2006: Immunogen, Inc. Announces Achievement Of Milestone In Collaboration With Genentech; Trastuzumab-Dm1 Ind Becomes Effective, Triggering $2 Million Payment To Immunogen 122
Jan 24, 2003: Immunogen, Inc. Regains Development And Commercialization Rights For Cantuzumab Mertansine 123
Jan 23, 2002: Immunogen, Inc. Receives Patent On Taxane Compounds 123
Jan 15, 2003: Immunogen, Inc. Announces Publication Of Cantuzumab Mertansine Phase I Study In The Journal Of Clinical Oncology 124
Jan 04, 2002: Immunogen, Inc. Receives Patent On Production Of Dm1 125
Clinical Trials 125
Dec 04, 2010: ImmunoGen Presents Positive Initial Clinical Data For IMGN901 Used In Combination Regimen For Multiple Myeloma 125
Nov 30, 2010: ImmunoGen Initiates Phase I/II Clinical Trial Of IMGN901 In Small-Cell Lung Cancer 126
Nov 19, 2010: ImmunoGen Presents Phase I Data Of IMGN388 At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 127
Jun 07, 2010: ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported At ASCO 127
Dec 06, 2009: ImmunoGen, Inc. Announces Encouraging Clinical Data With Its IMGN901 Compound In The Treatment Of Multiple Myeloma 128
Jul 31, 2009: ImmunoGen Announces Encouraging New Clinical Data With IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer 129
Jun 11, 2009: ImmunoGen, Inc. Announces The Discontinuation Of Further Internal Development Of Its IMGN242 Compound 129
Dec 08, 2008: ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings 130
Jul 07, 2008: ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing 130
Jun 01, 2008: ImmunoGen, Inc. Announces Phase II Clinical Findings With Targeted Anticancer Compounds IMGN242 131
Jun 01, 2008: ImmunoGen, Inc. Announces The Phase 1 Clinical Findings At ASCO With Targeted Anticancer Compound AVE1642 131
Dec 09, 2007: ImmunoGena Announces The Clinical Findings With The TAP Compound AVE9633. 132
Dec 08, 2007: ImmunoGen, Inc. Announces Encouraging Clinical Findings For Targeted Anticancer Compounds IMGN901 (HuN901-DM1) And AVE1642 132
Dec 08, 2007: ImmunoGen, Inc. Announces Encouraging Phase I Clinical Findings Of AVE1642 133
Aug 01, 2007: ImmunoGen, Inc. Initiates Phase II Clinical Trial Of HuC242-DM4 134
Oct 04, 2006: ImmunoGen Announces Initiation Of Clinical Testing Of AVE1642 Anticancer Compound In Collaboration With Sanofi-Aventis. 134
Jun 24, 2005: ImmunoGen, Inc. Announces Initiation Of Clinical Testing Of Its HuC242-DM4 Anticancer Compound; Company's Second Wholly-Owned TAP Compound Advances Into Clinical Testing 134
May 19, 2005: ImmunoGen, Inc. Announces Presentation Of Preclinical Results Of AVE9633 135
Apr 19, 2005: mmunoGen, Inc. Announces Data Reported at AACR on AVE9633 Anticancer Compound 135
Aug 08, 2002: ImmunoGen, Inc. And British Biotech Announce Initiation Of Second Phase I Study Of huN901-DM1/BB-10901 136
Nov 10, 2001: ImmunoGen Reports Preliminary Phase I/II Clinical Data On huC242-DM1/SB-408075 136
Nov 01, 2001: ImmunoGen Announces Favorable Preliminary Phase I/II Data On huC242-DM1/SB-408075 137
May 14, 2001: ImmunoGen Reports Promising Results from Phase I/II Human Clinical Study with Product Candidate for Colorectal, Pancreatic and Non-Small-Cell Lung Cancers 138
May 08, 2001: ImmunoGen Begins Enrollment In A Third Phase I/II Human Clinical Study With Lead Product For Colorectal, Pancreatic And Non-Small-Cell Lung Cancers 138
Sep 21, 2000: HuC242-DM1/SB-408075 Enters Second Phase I/II Clinical Trial 139
Appendix 140
Methodology 140
About GlobalData 140
Contact Us 140
Disclaimer 140

List of Tables

ImmunoGen, Inc., Pharmaceuticals & Healthcare, Key Facts, 2011 1
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 1
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012 1
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2006 to YTD 2012 1
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 9
ImmunoGen, Inc., Pharmaceuticals & Healthcare Deals By Type, 2006 to YTD 2012 10
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012 11
ImmunoGen, Inc., Deals By Therapy Area, 2006 to YTD 2012 12
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 13
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 13
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 14
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 14
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 15
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 15
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 16
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 16
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 17
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012 17
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2006 to YTD 2012 18
ImmunoGen Enters Into Partnership With Novartis 19
Sanofi-Aventis Extends Research Collaboration With ImmunoGen 20
ImmunoGen Extends Its License Agreement With Sanofi-Aventis 21
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 22
ImmunoGen Enters Into Second Licensing Agreement With Amgen 23
ImmunoGen Enters Into Licensing Agreement With Amgen 24
ImmunoGen Enters Into Licensing Agreement With Genentech For Cancer Technology 25
ImmunoGen Enters Into Licensing Agreement With Bayer HealthCare 26
ImmunoGen Enters Into Licensing Agreement With Centocor Ortho Biotech 27
ImmunoGen Enters Into Licensing Agreement With Sanofi-Aventis 29
ImmunoGen Enters Into Licensing Agreement With Biotest 30
ImmunoGen Extends Its Agreement With Millennium Pharmaceuticals 31
ImmunoGen Completes An Underwritten Public Offering Of $84 Million 32
ImmunoGen Completes Public Offering Of $83 Million 34
ImmunoGen Completes Public Offering Of $40 Million 36
ImmunoGen Completes Private Placement Of $25 Million 38
ImmunoGen, Inc., Key Competitors 40
ImmunoGen, Inc., Key Employees 41
ImmunoGen, Inc., Other Locations 42

List of Figures

ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012 1
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Year, 2006 to YTD 2012 1
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Licensing Deals by Phase, 2006 to YTD 2012 1
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 9
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012 10
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012 11
ImmunoGen, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2006 to YTD 2012 12

Cancer in United Kingdom

United Kingdom Prostate Cancer, 5-14 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Prostate Cancer, 45-59 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Prostate Cancer, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Prostate Cancer, 0-4 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Pancreatic Cancer, 60-69 Yrs, Total, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

Pathology in United Kingdom

United Kingdom Respiratory Diseases, 70+ Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Post-traumatic Stress Disorder, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Peptic Ulcer Disease, 15-29 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Respiratory Infections, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom

United Kingdom Protein-energy Malnutrition, 30-44 Yrs, Male, Dalys

• $ 250
• Industry data
• May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

• Industries : Pathology
• Countries : United Kingdom